The Little Green Pharma court case has seen its initial formal step with orders in favour of its intended takeover of Cannatrek Ltd, having been obtained by Little Green Pharma Ltd.
The affirmation of the first court hearing result by the company paved the way for shareholders to vote on the offered scheme of arrangement.
It is a full acquisition of the issued capital of 100 per cent of Cannatrek under Part 5.1 of the Corporations Act 2001 (Cth). The legal framework and punctuality are given in the ruling. Shareholders can now see how the process is going.
The news is a milestone in the Little Green Pharma development and offers a positive credit in the direction of the medicinal cannabis market consolidation in Australia this week.
Little Green Pharma’s production and corporate operations highlight its vertically integrated cannabis platform. [MMJDaily]
How Did The Court Support The Little Green Pharma Court Case?
The Supreme Court of Victoria has directed a Cannatrek shareholder meeting to convene and gave approval to the dispatching of the explanatory statement. The ruling enables the Scheme Booklet and meeting notice to be dispatched to the qualified investors.
The terms of the transactions and the way of voting are described in this booklet. It also describes risks and special discoveries. The order is a successful way of launching the formal schedule. In the absence of this approval, the acquisition could not proceed to a vote.
The result is thus the legal access to the scheme. Such initial hearings are usually considered procedural yet critical by market players since they guarantee that standards of compliance and fairness are achieved.
When And Where Will Cannatrek Shareholders Vote?
The Scheme Meeting shall take place in person and by way of video conference on 10 April 2026 at 9.30 am in Melbourne time. The residential location is K&L Gates, 25/525s Collins Street, Melbourne VIC 3000, which can be accessed online by Lumiconnect.
Shareholders in Cannatrek who have registered at 7.00 pm (Melbourne time), 8 April 2026, are entitled to vote.
Proxies should not be submitted within a time of less than 48 hours prior to the meeting. Early lodgement of proxies by the management is encouraged. Elaborated participation guidelines shall be found within the Scheme Booklet.
The booklet is supposed to be registered at the Australian Securities and Investments Commission on 4 March 2026. It will be announced after registration on the ASX announcements and the company’s website.
Melbourne meeting and virtual access options enable broad shareholder participation. [NovoJuris]
LGP Shareholders Prepare For Separate Approval Meeting
The resolutions associated with the scheme that will be voted on by the Little Green Pharma shareholders will also be subject to. The meeting of the LGP will be held on 10 April 2026, 3.00 pm (Perth time) through the Zoom webinar.
The eligibility is established at 3.00 pm (Perth time) on 8 April 2026. Directed proxies are 48 hours prior to the meeting. The company shall notify of the meeting and have an explanatory memorandum when the booklets are registered.
These measures match the approvals of the two companies on the same day. The dual structure minimises the delays and enhances the certainty of execution. It also makes sure that the standards of governance occur on either side of the transaction.
This synchronised schedule is a cohesive Little Green Pharma legal update that attempts to reduce risk.
What Do The Boards Recommend To Investors?
The two boards have unanimously given a recommendation to support their resolutions. The Cannatrek Board approves the scheme without a Superior Proposal and on the basis of the decision of the Independent Expert.
All controlled shares will be voted in favour by each Director of Cannatrek. A similar recommendation has been made by the LGP Board to the shareholders. All the held or controlled shares will be voted in favour by each LGP Director, also in the absence of a Superior Proposal.
Retail sentiments are usually affected by such aligned endorsements. The intentions of directors to vote usually indicate confidence in the strategic value. Investors consequently consider such statements as positive.
Board endorsements suggest confidence in the strategic combination and future growth. [LinkedIn]
Indicative Timetable Sets Path To Implementation
The indicative schedule stipulates visible checkpoints. The inaugural sitting of the meeting at court was at 2:15 pm (Melbourne time) on 3 March 2026. The date of the Scheme Booklet is 4 March 2026.
The forms of Cannatrex proxy have expired by 9.30 am (Melbourne time) on 8 April 2026. Forms of LGP proxy are returned by 3.00 pm (Perth time) on 8 April 2026. Both meetings occur on 10 April 2026.
In case it is approved by shareholders, the Second Court Date is 9:30 am (Melbourne time) on 21 April 2026. The Effective Date is 22 April 2026. The Scheme Record Date is 7.00 pm (Melbourne time), 24 April 2026.
Date of Implementation and delivery of Consideration Securities: 1 May 2026. These milestones set the basis of investor expectations and situate the next phase of Little Green Pharma news as the company pursues its strategy to expand.
Also Read: Santos Locks In 10-Year Gas Deal to Fuel Whyalla Steelworks’ Green Iron Ambition
FAQs
Q1. What is the Little Green Pharma court case about?
A1: It concerns court approval for a scheme allowing Little Green Pharma to acquire Cannatrek.
Q2. When is the Cannatrek shareholder vote?
A2: The vote occurs on 10 April 2026 at 9.30 am (Melbourne time).
Q3. When will the scheme become effective if approved?
A3: The Effective Date is 22 April 2026, subject to court approval.
Q4. When will consideration securities be issued?
A4: The Implementation Date is 1 May 2026.
